IL263433B2 - Methods for treating alzheimer's disease - Google Patents

Methods for treating alzheimer's disease

Info

Publication number
IL263433B2
IL263433B2 IL263433A IL26343318A IL263433B2 IL 263433 B2 IL263433 B2 IL 263433B2 IL 263433 A IL263433 A IL 263433A IL 26343318 A IL26343318 A IL 26343318A IL 263433 B2 IL263433 B2 IL 263433B2
Authority
IL
Israel
Prior art keywords
subject
antibody
body weight
aria
weeks
Prior art date
Application number
IL263433A
Other languages
English (en)
Hebrew (he)
Other versions
IL263433A (en
IL263433B1 (en
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of IL263433A publication Critical patent/IL263433A/en
Publication of IL263433B1 publication Critical patent/IL263433B1/en
Publication of IL263433B2 publication Critical patent/IL263433B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL263433A 2016-06-07 2017-06-06 Methods for treating alzheimer's disease IL263433B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346818P 2016-06-07 2016-06-07
US201662435531P 2016-12-16 2016-12-16
PCT/EP2017/063711 WO2017211827A1 (en) 2016-06-07 2017-06-06 Methods for treating alzheimer's disease

Publications (3)

Publication Number Publication Date
IL263433A IL263433A (en) 2019-01-31
IL263433B1 IL263433B1 (en) 2023-11-01
IL263433B2 true IL263433B2 (en) 2024-03-01

Family

ID=59067640

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263433A IL263433B2 (en) 2016-06-07 2017-06-06 Methods for treating alzheimer's disease

Country Status (12)

Country Link
US (2) US20200308259A1 (enExample)
EP (1) EP3464350A1 (enExample)
JP (3) JP2019517540A (enExample)
KR (2) KR20230165883A (enExample)
CN (3) CN114931635A (enExample)
AU (2) AU2017276656A1 (enExample)
BR (1) BR112018075300A2 (enExample)
CA (1) CA3026598A1 (enExample)
IL (1) IL263433B2 (enExample)
MA (1) MA45149A (enExample)
MX (1) MX2018015022A (enExample)
WO (1) WO2017211827A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3696192A1 (en) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
JOP20210265A1 (ar) 2019-03-26 2023-01-30 Janssen Pharmaceutica Nv الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
EP4048695A1 (en) * 2019-10-22 2022-08-31 Biogen MA Inc. Anti-beta-amyloid antibody for treating alzheimer's disease
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
KR102321601B1 (ko) * 2020-11-19 2021-11-05 주식회사 휴런 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법
WO2022261026A2 (en) * 2021-06-07 2022-12-15 Biogen Ma Inc. Methods for treating alzheimer's disease
US20250122146A1 (en) * 2021-09-30 2025-04-17 The Scripps Research Institute Compounds for reducing neuroinflammation
KR20240101629A9 (ko) * 2021-11-19 2025-12-10 에이피 바이오사이언시스, 아이엔씨. Cd137을 표적화하는 이중특이적 항체 및 항암 면역요법을 위한 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089500A1 (en) * 2012-12-07 2014-06-12 Biogen Idec International Neuroscience Gmbh A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2046833T1 (sl) * 2006-07-14 2013-12-31 Ac Immune S.A. Humanizirano protitelo proti amiloidu beta
SG177954A1 (en) * 2007-01-05 2012-02-28 Univ Zuerich Method of providing disease-specific binding molecules and targets
MX345092B (es) 2010-10-11 2017-01-17 Univ Zuerich Anticuerpos anti-tau humanos,.
EP2906597B1 (en) * 2012-10-15 2020-04-08 Medimmune Limited Antibodies to amyloid beta
ES2816700T3 (es) 2012-12-21 2021-04-05 Biogen Ma Inc Anticuerpos anti-tau humanos
KR20160111039A (ko) * 2014-02-08 2016-09-23 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089500A1 (en) * 2012-12-07 2014-06-12 Biogen Idec International Neuroscience Gmbh A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JACOPO C. DIFRANCESCO ET AL., " ANTI-A[BETA] AUTOANTIBODIES IN AMYLOID RELATED IMAGING ABNORMALITIES IN ALZHEIMER'S DISEASE AND CEREBRAL AMYLOID ANGIOPATHY", 25 September 2015 (2015-09-25) *
PIAZZA FABRIZIO ET AL, " AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA) IN IMMUNOTHERAPY TRIALS FOR ALZHEIMER'S DISEASE: NEED FOR PROGNOSTIC BIOMARKERS ?", 29 March 2016 (2016-03-29) *
SEVIGNY JEFF ET AL., " ADUCANUMAB [BIIB037], AN ANTI-AMYLOID BETA MONOCLONAL ANTIBODY, IN PATIENTS WITH PRODROMAL OR MILD ALZHEIMER'S DISEASE: INTERIM RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1B STUDY", 22 July 2015 (2015-07-22) *
SEVIGNY JEFFREY J ET AL., " RANDOMIZED,DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1B STUDY OF ADUCANUMAB (BIIB037), AN ANTI-AB MONOCLONAL ANTIBODY, IN PATIENTS WITH PRODROMAL OR MILD ALZHEIMER'S DISEASE: INTERIM RESULTS BY DISEASE STAGE AND APOE4 STATUS" ,, 1 July 2015 (2015-07-01) *

Also Published As

Publication number Publication date
CN109476730A (zh) 2019-03-15
IL263433A (en) 2019-01-31
WO2017211827A1 (en) 2017-12-14
KR20190021311A (ko) 2019-03-05
AU2017276656A1 (en) 2018-12-13
KR20230165883A (ko) 2023-12-05
CA3026598A1 (en) 2017-12-14
CN114796481A (zh) 2022-07-29
US20220281963A1 (en) 2022-09-08
JP2019517540A (ja) 2019-06-24
MX2018015022A (es) 2019-08-14
IL263433B1 (en) 2023-11-01
MA45149A (fr) 2019-04-10
US20200308259A1 (en) 2020-10-01
AU2024216442A1 (en) 2024-10-17
BR112018075300A2 (pt) 2019-04-30
JP2025160337A (ja) 2025-10-22
JP2022145965A (ja) 2022-10-04
EP3464350A1 (en) 2019-04-10
CN114931635A (zh) 2022-08-23

Similar Documents

Publication Publication Date Title
US20220281963A1 (en) Methods for treating alzheimer's disease
US10842871B2 (en) Methods for treating Alzheimer's disease
US20220372123A1 (en) Anti-beta-amyloid antibody for treating alzheimer's disease
JP2024540294A (ja) アルツハイマー病を治療するための方法
EP4473009A1 (en) Methods of treatment using p-tau181 level
NZ788486A (en) Methods for treating Alzheimer's disease
US20240270830A1 (en) Methods for treating alzheimer's disease